Our fundamental purpose is to find and fund viable assets developed by ethical and ingenious entrepreneurs that improve patient outcome and increase quality of healthcare.
From bench to bedside
We seek therapeutic assets and devices with established proof-of-concept and with established or disected mechanism of action, regardless of size of molecule or medical indication.
We strive for funding modern medical devices that lead to quicker recovery times, reduced pain and improved quality of life and facilitate personalized, data-driven healthcare decisions.
We aim to find advanced technologies that significantly enhance diagnosis and treatment precision, allowing for early detection of diseases and more targeted interventions.
We seek companies that improve health care outcomes by utilizing real time data and sophisticated AI methodology as well as optimize work flow to address evolving health care challenges.
Our strategy is dedicated to investing in cutting-edge medical technologies and therapies that have the potential to revolutionize healthcare, decrease morbidity, improve quality of life and extend human lifespan.
Gennady Bratslavsky, MD
Founder & Managing Partner, North America
National Cancer Institute/National Institutes of Health trained urologic surgeon-scientist, entrepreneur, clinical investigator. Professor of Urology, Molecular Biology and Biochemistry. Author of over 200 scientific peer reviewed articles and book chapters and invited presenter at over 100 international conferences. Co- inventor of several patents in the field of AI technology, devices, antibody methodology, and small molecules.
Partner & COO, North America
Ms. Raphael has nearly 20 years experience in pharmaceutical development with deep understanding of the clinical development process from lead optimization to commercialization. She was involved in aspects of business development, M&A and transactions, and she has a rich knowledge of immunotherapies, biologics, cell therapy, and targeted agents. Most recently, she was a member of the leadership team and Vice President of Strategy & Operations at Promontory Therapeutics where she led the commercial and clinical operations teams. She also held various commercial, business development, and clinical development positions at Celgene (acquired by BMS) and at Intercept Pharmaceuticals.
Ms. Raphael has a BS from Tufts University, MS in Biomedical Engineering from Columbia University and MBA from Columbia Business School.
Co-Founder & Partner, Europe
Mr. Saab is a successful serial entrepreneur in different businesses and has extensive experience in the financial industry. He started his career in January 2005 working in fixed income trading at JP Morgan. He then worked for Rothschild multi-asset solutions from December 2007 to June 2011, managing portfolios for international institutional clients and Ultra High Net Worth clients. He rejoined JP Morgan in 2011 and became one of the youngest Managing Directors in the private bank. He was elected Fixed Income personality of the year in the United Kingdom in 2017.
In 2018, Mr. Saab cofounded Aperture Investors, in which Generali Investments committed a $4 billion seed investment. Aperture Investments was a new asset manager aiming to disrupt the financial market by aligning fees paid by the clients with performance generated by portfolio managers. More recently, in May 2021 he established Alumia, a platform that helps asset managers raise assets in the international market. Mr. Saab acts as an advisor to a large number of institutional investors and family offices around the world. He successfully worked on very complex transactions in different sectors, helping principals sell or restructure their businesses. He is co-founder and director of several financial companies including clean earth acquisition corp and SMRF